Millions of Americans use compounded GLP-1s. Stanford Health Care weighs in on the questions these copies raise.
Recap by typeshit. Post by Stanford Health Care on X.
He describes a case where a product sourced from neither Eli Lilly nor a compounding pharmacy was followed by liver failure within six days.
The pharmacists' group says the drug looks promising but urges patients to understand what they risk with unofficial sources, and points to its SafeMedication site.
The pharmacists' group points people to its SafeMedication site for a patient-friendly explainer on retatrutide and why unofficial sources are risky.
He says the woman's retatrutide came from neither Lilly nor a compounding pharmacy, and her liver failed within six days of starting it.
Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
A Halloween joke from the obesity doctor with a photo attached. Light on substance, but a familiar voice in the GLP-1 conversation.
Loading…